DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
Zacopride hydrochloride (HB1694)
Description:Potent 5-HT3 antagonist and 5-HT4 agonist. Also selective IK1 channel agonist.
Purity:>99%
-
Ziprasidone hydrochloride (HB1753)
Description:5-HT2A and D2 antagonist. Atypical antipsychotic.
Purity:>99%
-
-
Zotepine (HB1778)
Description:5-HT2A and dopamine D2 receptor antagonist. Atypical antipsychotic.
Purity:>99%
-
-
Diphenhydramine hydrochloride (DPH) (HB2617)
Description:Histamine H1 antagonist. Potent actuator of a modified hM4Di "GRANPA" DREADD receptor.
Purity:>99%
